IP Library Granted Patent US 11,352,674
Granted Patent B2
US 11,352,674 · App. 16/814,798 · Granted Jun 7, 2022

Multiplexed KRAS mutation detection assay

Inventors: Rebecca Oldham-Haltom (Marshall, WI); Hatim Allawi (Madison, WI); Hongzhi Zou (Middleton, WI); Michael J. Domanico (Madison, WI); Graham P. Lidgard (Madison, WI)
Assignee: Exact Sciences Development Company, LLC
C12Q1/6886C12Q1/6858C12Q2600/156C12Q2600/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,352,674
App. No.
16/814,798
Granted
Jun 7, 2022
Kind
B2
Abstract

Provided herein is reagent mixture comprising multiplexed amplification reagents and flap assay reagents for detecting, in a single reaction, mutant copies of the KRAS gene that contain any of the 34A, 34C, 34T, 35A, 35C, 35T or 38A point mutations. Methods that employ the reagent mix and kits for performing the same are also provided.

Claims (14)

1. A kit comprising:

at least seven different oligonucleotides, wherein the oligonucleotides each comprise at least 12 contiguous nucleotides from the 3′ end of a sequence as set forth in SEQ ID NOs: 11-17 or their complements, wherein the oligonucleotides are in one or more containers.

2. The kit of claim 1 , wherein the oligonucleotides are in separate containers.

3. The kit of claim 1 , wherein the oligonucleotides are in the same container.

4. The kit of claim 1 , wherein the oligonucleotides each comprise a sequence selected from SEQ ID NOS: 11-17.

5. The kit of claim 1 , wherein the kit further comprises forward and reverse primers that each hybridize to the human KRAS gene.

6. The kit of claim 1 , wherein the kit further comprises a thermostable polymerase.

7. The kit of claim 1 , wherein the kit further comprises deoxynucleotide triphosphates.

8. A composition comprising:

at least seven different oligonucleotides, wherein the oligonucleotides each comprise at least 12 contiguous nucleotides from the 3′ end of a sequence as set forth in SEQ ID NOs: 11-17 or their complements.

9. The composition of claim 8 , wherein the oligonucleotides each comprise a sequence selected from SEQ ID NOS: 11-17.

10. The composition of claim 8 , wherein the composition further comprises forward and reverse primers that each hybridize to the human KRAS gene.

11. The composition of claim 8 , wherein the composition further comprises a thermostable polymerase.

12. The composition of claim 8 , wherein the composition further comprises deoxynucleotide triphosphates.

Assignments (5)
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENT RIGHTS (REEL/FRAME 69898/0249) Recorded Mar 27, 2026
From: JPMORGAN CHASE BANK, N.A.
To: EXACT SCIENCES CORPORATION
Reel/Frame 075288/0393 →
PATENT SECURITY AGREEMENT Recorded Jan 14, 2025
From: EXACT SCIENCES CORPORATION
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 069898/0249 →
MERGER Recorded Nov 8, 2022
From: EXACT SCIENCES DEVELOPMENT COMPANY, LLC
To: EXACT SCIENCES CORPORATION
Reel/Frame 061692/0163 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2020
From: OLDHAM-HALTOM, REBECCA; ALLAWI, HATIM; ZOU, HONGZHI; DOMANICO, MICHAEL J.; LIDGARD, GRAHAM P.
To: EXACT SCIENCES CORPORATION
Reel/Frame 052102/0319 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2020
From: EXACT SCIENCES CORPORATION
To: EXACT SCIENCES DEVELOPMENT COMPANY, LLC
Reel/Frame 052102/0357 →